Matches in Wikidata for { <http://www.wikidata.org/entity/Q73716666> ?p ?o ?g. }
Showing items 1 to 58 of
58
with 100 items per page.
- Q73716666 description "artículu científicu espublizáu en setiembre de 1997" @default.
- Q73716666 description "im September 1997 veröffentlichter wissenschaftlicher Artikel" @default.
- Q73716666 description "scientific article published on 01 September 1997" @default.
- Q73716666 description "wetenschappelijk artikel" @default.
- Q73716666 description "наукова стаття, опублікована у вересні 1997" @default.
- Q73716666 name "Gabapentin monotherapy: II. A 26-week, double-blind, dose-controlled, multicenter study of conversion from polytherapy in outpatients with refractory complex partial or secondarily generalized seizures. The US Gabapentin Study Group 82/83" @default.
- Q73716666 name "Gabapentin monotherapy: II. A 26-week, double-blind, dose-controlled, multicenter study of conversion from polytherapy in outpatients with refractory complex partial or secondarily generalized seizures. The US Gabapentin Study Group 82/83" @default.
- Q73716666 type Item @default.
- Q73716666 label "Gabapentin monotherapy: II. A 26-week, double-blind, dose-controlled, multicenter study of conversion from polytherapy in outpatients with refractory complex partial or secondarily generalized seizures. The US Gabapentin Study Group 82/83" @default.
- Q73716666 label "Gabapentin monotherapy: II. A 26-week, double-blind, dose-controlled, multicenter study of conversion from polytherapy in outpatients with refractory complex partial or secondarily generalized seizures. The US Gabapentin Study Group 82/83" @default.
- Q73716666 prefLabel "Gabapentin monotherapy: II. A 26-week, double-blind, dose-controlled, multicenter study of conversion from polytherapy in outpatients with refractory complex partial or secondarily generalized seizures. The US Gabapentin Study Group 82/83" @default.
- Q73716666 prefLabel "Gabapentin monotherapy: II. A 26-week, double-blind, dose-controlled, multicenter study of conversion from polytherapy in outpatients with refractory complex partial or secondarily generalized seizures. The US Gabapentin Study Group 82/83" @default.
- Q73716666 P1433 Q73716666-9E278884-09F4-4F3F-8926-6B9773A30D2B @default.
- Q73716666 P1476 Q73716666-A6B733FE-3895-4C37-B1C1-EE698C6F1D54 @default.
- Q73716666 P2093 Q73716666-13FDE9E2-75EA-4E81-8E68-19B55E415399 @default.
- Q73716666 P2093 Q73716666-176B52CF-0C8A-4C0E-933A-359F85005228 @default.
- Q73716666 P2093 Q73716666-208747EA-C422-4EE9-8DA5-ED6F91C9D6DE @default.
- Q73716666 P2093 Q73716666-571E2904-E8F8-46A0-AA57-09BF11DB3438 @default.
- Q73716666 P2093 Q73716666-6975B16D-425F-4C00-9EF7-1BBDF797C631 @default.
- Q73716666 P2093 Q73716666-848753B7-82CF-4748-B600-AD6945F30352 @default.
- Q73716666 P2093 Q73716666-8D504BE8-78B4-4B07-97FB-14653DB40895 @default.
- Q73716666 P2093 Q73716666-983AA4E0-C275-4D92-B68C-D9BECD67B09B @default.
- Q73716666 P2093 Q73716666-A64B50E0-790C-4320-93C6-83E6EA216D42 @default.
- Q73716666 P2093 Q73716666-A84DC139-2D52-4DBD-BD41-593155C5CBD5 @default.
- Q73716666 P2093 Q73716666-CB250D82-3851-4BC9-88D1-E73535C19338 @default.
- Q73716666 P2093 Q73716666-D772FB48-2BBE-40A8-976F-ABC68520901D @default.
- Q73716666 P2093 Q73716666-F6AD2366-EF31-455A-8190-7834B1345EE5 @default.
- Q73716666 P304 Q73716666-276CD335-039A-491C-B1A9-570E7EA15BC9 @default.
- Q73716666 P31 Q73716666-3BE44312-EBC8-4C65-ADCA-DE743AACB29F @default.
- Q73716666 P356 Q73716666-E678C201-5D03-4F5D-9A96-0B054EF78312 @default.
- Q73716666 P433 Q73716666-C40D11E8-2C9C-4F35-A88B-FFE6C18624C3 @default.
- Q73716666 P478 Q73716666-0414C641-EF0B-4F62-A87C-9DC3A910D775 @default.
- Q73716666 P577 Q73716666-05A75B96-FF32-429B-8380-12872A3D3933 @default.
- Q73716666 P698 Q73716666-8C8244B6-A813-43BF-8568-0ECC718DF8A2 @default.
- Q73716666 P356 WNL.49.3.746 @default.
- Q73716666 P698 9305335 @default.
- Q73716666 P1433 Q1161692 @default.
- Q73716666 P1476 "Gabapentin monotherapy: II. A 26-week, double-blind, dose-controlled, multicenter study of conversion from polytherapy in outpatients with refractory complex partial or secondarily generalized seizures. The US Gabapentin Study Group 82/83" @default.
- Q73716666 P2093 "A Beydoun" @default.
- Q73716666 P2093 "A Hayes" @default.
- Q73716666 P2093 "B Abou-Khalil" @default.
- Q73716666 P2093 "B M Uthman" @default.
- Q73716666 P2093 "C Harden" @default.
- Q73716666 P2093 "D Cantrell" @default.
- Q73716666 P2093 "D R Labar" @default.
- Q73716666 P2093 "E Garofalo" @default.
- Q73716666 P2093 "J C Sackellares" @default.
- Q73716666 P2093 "J Fischer" @default.
- Q73716666 P2093 "M Greiner" @default.
- Q73716666 P2093 "M Pierce" @default.
- Q73716666 P2093 "R E Ramsay" @default.
- Q73716666 P304 "746-752" @default.
- Q73716666 P31 Q13442814 @default.
- Q73716666 P356 "10.1212/WNL.49.3.746" @default.
- Q73716666 P433 "3" @default.
- Q73716666 P478 "49" @default.
- Q73716666 P577 "1997-09-01T00:00:00Z" @default.
- Q73716666 P698 "9305335" @default.